Serina Therapeutics, Inc. (SER) - 10-Q Summary
Business Context and Reporting Period
Company: Serina Therapeutics, Inc.
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: A clinical-stage biotechnology company developing a pipeline of drug candidates for neurological diseases and pain using its proprietary POZ (poly(2-oxazoline)) drug delivery technology. The Company is currently focused on advancing its lead candidate, SER-252 (POZ-apomorphine), for Parkinson's disease.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Total Revenues | $130 | $51 | $130 | $56 |
| Net Loss (Attributable to Serina) | $(6,448) | $5,204 (Income) | $(11,261) | $(9,811) |
| Operating Expenses | $5,695 | $3,917 | $11,553 | $6,243 |
| Cash and Cash Equivalents (End of Period) | $6,041 | $6,114 | $6,041 | $6,114 |
| Net Cash Used in Operating Activities | N/A | N/A | $(8,072) | $(9,586) |
| Net Cash Provided by Financing Activities | N/A | N/A | $10,487 | $8,095 |
| Warrant Liability | $3,549 | $13,413 | $3,549 | $13,413 |
Note: Q2 2024 net income was driven by a $9.3 million gain on the change in fair value of warrants. Q2 2025 net loss includes a $1.0 million loss on warrant fair value changes.
Material Changes vs. Prior Period
- Revenue: Grant revenues increased to $130,000 in Q2 2025 from $51,000 in Q2 2024.
- Operating Expenses: Total operating expenses rose significantly to $5.7 million in Q2 2025 from $3.9 million in Q2 2024.
- R&D: Increased to $3.2 million (from $1.6 million) due to higher outside research services, consultant spend, and personnel costs.
- G&A: Increased to $2.5 million (from $2.3 million) driven by stock-based compensation and consulting fees, partially offset by lower legal fees.
- Net Income/Loss: The Company reported a net loss of $6.5 million in Q2 2025, compared to net income of $5.2 million in Q2 2024. The prior year income was largely non-cash, resulting from a $9.3 million gain on warrant fair value adjustments, whereas the current quarter included a $1.0 million loss on similar adjustments.
- Financing: In Q2 2025, the Company raised approximately $5.6 million through the issuance of Series A Convertible Preferred Stock ($4.9 million net) and an At-The-Market (ATM) offering ($0.6 million net).
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern. Cash on hand of $6.0 million is not expected to be sufficient to fund operations for the next 12 months. Additional financing is required to continue development.
- Capital Raises:
- Series A Preferred Stock: Issued 965,250 shares in April 2025 at $5.18/share. These shares carry an 8% cumulative dividend (payable in stock) starting March 31, 2026, and have a $5.0 million liquidation preference.
- ATM Program: Entered into an agreement to sell up to $13.3 million of common stock. Sold 124,454 shares for $0.6 million net proceeds as of June 30, 2025.
- Internal Controls: The Company identified material weaknesses in internal controls over financial reporting as of June 30, 2025, citing insufficient qualified accounting personnel, lack of data validation, and inadequate segregation of duties. A remediation plan is underway.
- Unusual Items: Significant volatility in "Other (Expense) Income" due to fair value adjustments of warrant liabilities. The Company also derecognized $1.8 million in warrant liabilities in late 2024 upon surrendering warrants to Juvenescence in exchange for new Replacement Incentive Warrants.
- Outlook: The Company plans to advance SER-252 into Phase 1 clinical trials in 2025. Expenses are expected to increase as the Company hires additional personnel and advances clinical programs.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "substantial doubt" going concern warning and $6.0 million cash balance.
- Dilution Risk: Assess the impact of the Series A Preferred Stock (8% PIK dividends) and the outstanding warrant liabilities ($3.5 million) on future equity dilution.
- Internal Controls: Monitor the progress of the remediation plan for material weaknesses in financial reporting, which could impact future filing reliability.
- Expense Trajectory: Confirm if the 98% increase in R&D expenses year-over-year is sustainable without immediate revenue generation.
- Warrant Liability Volatility: Understand how fluctuations in the Company's stock price will continue to impact the "Other Income/Expense" line item via warrant fair value adjustments.